Skip to main content

EGFL7 KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 4 and Insertion of the selection cassette in exon 4.

Be the first to review this product! Submit a review

Images

Sanger Sequencing - Human EGFL7 knockout HeLa cell line (AB264899), expandable thumbnail
  • Sanger Sequencing - Human EGFL7 knockout HeLa cell line (AB264899), expandable thumbnail

Key facts

Cell type
HeLa
Species or organism
Human
Tissue
Cervix
Form
Liquid
Knockout validation
Sanger Sequencing, Western blot
Mutation description
Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 4 and Insertion of the selection cassette in exon 4

Recommended products

EGFL7 KO cell line available to order. KO validated by Western blot. Free of charge wild type control provided. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 4 and Insertion of the selection cassette in exon 4.

Key facts

Cell type
HeLa
Form
Liquid
Mutation description
Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 4 and Insertion of the selection cassette in exon 4
Disease
Adenocarcinoma
Concentration
Loading...

Properties

Gene name
EGFL7
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot

Cell culture

Biosafety level
EU: 2 US: 2
Viability
~ 80%
Adherent/suspension
Adherent
Gender
Female

Handling procedures

Initial handling guidelines

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.
2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.
3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.
4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.
5. Once confluent passage into an appropriate flask at a density of 2x104 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.

Subculture guidelines
  • All seeding densities should be based on cell counts gained by established methods.
  • A guide seeding density of 2x104 cells/cm2 is recommended.
  • Cells should be passaged when they have achieved 80-90% confluence.
Culture medium
DMEM (High Glucose) + 10% FBS
Cryopreservation medium
Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Storage

Shipped at conditions
Dry Ice
Appropriate short-term storage conditions
-196°C
Appropriate long-term storage conditions
-196°C

Notes

Although we aim to provide customers with a homozygous clone, feasibility will be dependent on the biology of the protein. Should only heterozygous edits be achieved, you will be notified of the outcome and be asked to confirm whether the cell line is acceptable. All clones will be accompanied with DNA sequencing data, and the mutation description.

Recommended control: Human wild-type HeLa cell line (ab255448). Please note a wild-type cell line is not automatically included with a knockout cell line order, if required please add recommended wild-type cell line at no additional cost using the code WILDTYPE-TMTK1.

Cryopreservation cell medium: Cell Freezing Medium-DMSO Serum free media, contains 8.7% DMSO in MEM supplemented with methyl cellulose.

Culture medium:  DMEM (High Glucose) + 10% FBS  

Initial handling guidelines:

Upon arrival, the vial should be stored in liquid nitrogen vapor phase and not at -80°C. Storage at -80°C may result in loss of viability.

1. Thaw the vial in 37°C water bath for approximately 1-2 minutes.

2. Transfer the cell suspension (0.8 mL) to a 15 mL/50 mL conical sterile polypropylene centrifuge tube containing 8.4 mL pre-warmed culture medium, wash vial with an additional 0.8 mL culture medium (total volume 10 mL) to collect remaining cells, and centrifuge at 201 x g (rcf) for 5 minutes at room temperature. 10 mL represents minimum recommended dilution. 20 mL represents maximum recommended dilution.

3. Resuspend the cell pellet in 5 mL pre-warmed culture medium and count using a haemocytometer or alternative cell counting method seed all remaining cells into a T25.

4. Incubate the culture at 37°C incubator with 5% CO2. Check the culture one day after revival and continue to check until 80% confluent. Media change can be given if needed.

5. Once confluent passage into an appropriate flask at a density of 2x10E4 cells/cm2. Seeding density is given as a guide only and should be scaled to align with individual lab schedules. Cultures should be monitored daily.  

Subculture guidelines:

• All seeding densities should be based on cell counts gained by established methods.

• A guide seeding density of 2x10E4 cells/cm2 is recommended.

• Cells should be passaged when they have achieved 80-90% confluence.

• Do not allow the cell density to exceed 7x10E4 cells/cm2.

We will provide viable cells that proliferate on revival.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

Supplementary info

This supplementary information is collated from multiple sources and compiled automatically.
Activity summary

EGFL7 also known as Epidermal Growth Factor-like Domain 7 is a secreted protein with a molecular mass of approximately 31 kDa. Scientists observe its expression mainly in vascular endothelial cells indicating its role in vasculature. It characterizes itself by its distinctive EGF-like repeat domains which enable interaction with other proteins in the cellular environment.

Biological function summary

EGFL7 plays an essential role in blood vessel development and maintenance. It is involved in the modulation of endothelial cell behavior primarily through cell proliferation migration and organization. EGFL7 influences angiogenesis by affecting the extracellular matrix environment but it does not form part of a larger protein complex. It serves as a regulator by interacting directly with other components of the angiogenic process.

Pathways

Research has established EGFL7 as a significant participant in the angiogenesis and Notch signaling pathways. It interacts closely with proteins such as COX-2 within the angiogenic pathway and through its efficacy impacts the downstream signaling events in vessels' formation and repair. The proper functioning of these pathways highlights the importance of EGFL7 in vascular biology.

Associated diseases and disorders

Researchers associate EGFL7 with certain cancers and cardiovascular diseases. Elevated levels of EGFL7 in tumors implicate it in tumor angiogenesis and metastasis suggesting its potential as a biomarker or therapeutic target. In cardiovascular contexts its interaction with VEGF suggests a role in pathologies involving vascular dysfunctions including atherosclerosis.

Product promise

We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.

In the unlikely event of one of our products not working as expected, you are covered by our product promise.

Full details and terms and conditions can be found here:
Terms & Conditions.

2 product images

  • Sanger Sequencing - Human EGFL7 knockout HeLa cell line (ab264899), expandable thumbnail

    Sanger Sequencing - Human EGFL7 knockout HeLa cell line (ab264899)

    Allele-1: 1 bp insertion in exon 4.

  • Sanger Sequencing - Human EGFL7 knockout HeLa cell line (ab264899), expandable thumbnail

    Sanger Sequencing - Human EGFL7 knockout HeLa cell line (ab264899)

    Allele-2: Insertion of the selection cassette in exon 4.

Downloads

Product protocols

For this product, it's our understanding that no specific protocols are required. You can:

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com